PNPO

Pyridoxine-5'-phosphate oxidase · Q9NVS9 · PNPO on Sugi Atlas →

243 patent compounds predicted against PNPO, 202 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15387271	0.68	1/20
SCHEMBL12727925	0.68	1/20
SCHEMBL30413789	0.68	1/20
SCHEMBL10906026	0.64	1/20
SCHEMBL20323319	0.64	1/20
SCHEMBL43880	0.63	1/20
SCHEMBL13176882	0.63	1/20
SCHEMBL29384180	0.63	1/20
Pyridoxal Phosphate Anhydrous (SCHEMBL23158)	0.61	1/20
Pyridoxamine Phosphate Anhydrous (SCHEMBL43832)	0.61	1/20
Water (SCHEMBL371432)	0.61	1/20
SCHEMBL6054139	0.61	1/20
Hydrochloric Acid (SCHEMBL14331173)	0.61	1/20
SCHEMBL16420385	0.61	1/20
Pyridoxal Phosphate Anhydrous (SCHEMBL29362986)	0.61	1/20
Pyridoxamine Phosphate Anhydrous (SCHEMBL29619879)	0.61	1/20
Ammonia Solution, Strong (SCHEMBL31241292)	0.61	1/20
Pyridoxal Phosphate Anhydrous (SCHEMBL827100)	0.60	1/20
Pyridoxal Phosphate Anhydrous (SCHEMBL2746592)	0.60	1/20
Pyridoxal Phosphate Anhydrous (SCHEMBL4916108)	0.60	1/20

Clinical trials — most relevant to PNPO by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy	PHASE4	COMPLETED
Short Course Low Dose Oral Colchicine After ST Elevation Myocardial Infarction(STEMI)	PHASE4	UNKNOWN
Pyridoxal Kinase Activity in Tardive Dyskinesia	PHASE3	WITHDRAWN
Addition of Pyridoxine to Prednisolone in Infantile Spasms	PHASE3	COMPLETED
Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria	PHASE3	WITHDRAWN
Multi-site Adaptive Trials for COVID-19	PHASE3	COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency	PHASE3	RECRUITING
Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda - 2012	PHASE2	WITHDRAWN
Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis	PHASE2	COMPLETED
A Trial of Pyridoxamine to Lower Urine Oxalate in Subjects With Stone Disease or Hyperoxaluria	PHASE2	WITHDRAWN
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults	EARLY_PHASE1	COMPLETED
Pyridoxine Effect on the Blood Glucose Level in Type 2 Diabetic Patients	nan	COMPLETED
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)	nan	APPROVED_FOR_MARKETING
The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes	nan	COMPLETED
Correlation of Genetic Polymorphism of Azathioprine Metabolizing Enzymes and Correlation to Clinical Adverse Effects	nan	COMPLETED
Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)	nan	WITHDRAWN
Natural History Study of Patients With Hypophosphatasia (HPP)	nan	RECRUITING
SPL Insufficiency Syndrome (SPLIS)/NPHS14: a SPLIS Observational Study and Patient Registry (International)	nan	RECRUITING
Egg Intake, Metabolic Outcomes and Choline Levels	nan	RECRUITING
Exome Sequencing for Atypical Femoral Fractures	nan	COMPLETED
The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin D in Preventing Preterm Birth:	nan	RECRUITING
Mucomyst for Hepatitis C	nan	SUSPENDED
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders	nan	RECRUITING
International Registry for Primary Hyperoxaluria	nan	WITHDRAWN
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
Study to Identify the Genetic Variations Associated With Phantom Limb Pain	nan	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PNPO binder may also engage these)

Protein	Name	Similarity
O88794	—	1.000	O88794 →
Q91XF0	—	1.000	Q91XF0 →
Q5E9K3	—	1.000	Q5E9K3 →
Q7MU50	—	0.993	Q7MU50 →
Q9UTQ1	—	0.988	Q9UTQ1 →
A1SUY2	—	0.988	A1SUY2 →
B2RHS7	—	0.988	B2RHS7 →
Q5PBF2	—	0.988	Q5PBF2 →
Q20939	—	0.988	Q20939 →
B3PSA1	—	0.987	B3PSA1 →
Q7UKQ9	—	0.987	Q7UKQ9 →
B9JAN3	—	0.987	B9JAN3 →
C3MHI2	—	0.987	C3MHI2 →
B4RVA4	—	0.987	B4RVA4 →
A2CDU4	—	0.987	A2CDU4 →
Q2N6B2	—	0.986	Q2N6B2 →
A8H5G0	—	0.986	A8H5G0 →
A4SWL7	—	0.986	A4SWL7 →
B0SPV0	—	0.986	B0SPV0 →
A7FHL9	—	0.986	A7FHL9 →
Q11KF1	—	0.986	Q11KF1 →
Q9PDP2	—	0.986	Q9PDP2 →
B1WR90	—	0.986	B1WR90 →
Q1PCB0	—	0.986	Q1PCB0 →
Q0BVM8	—	0.986	Q0BVM8 →
A1S710	—	0.985	A1S710 →
B8H292	—	0.985	B8H292 →
Q21WR9	—	0.985	Q21WR9 →
Q6D5V3	—	0.985	Q6D5V3 →
P38075	—	0.985	P38075 →